A piece of news
Investors assessed the possibility of joining equity holders in companies from the biotechnology, medical devices and healthcare sectors
Last Tuesday was the 14thHealthcare Investment Forum at the Barcelona Medical Association, promoted by the Barcelona Medical Association (COMB), ESADE BAN, Barcelona Activa–Barcelona City Council and Biocat. The forum brought together a selection of investors and businesspeople, who assessed the possibility of investing in eight companies from the biotechnology, medical devices and healthcare sectors.
The companies and entrepreneurs that participated in the forum are in the early stage or growing, and are seeking an injectimilion of capital to allow them to carry out their projects.
The first Healthcare Investment Forum took place in 2010 and since then, with data through the 12th edition, it has led to 13 operations and raised €9.2 millions.
In the 14th edition, Ankar Pharma –a start-up devoted to accelerating the process from drug discovery to market– was trying to raise the most capital, requesting a total of €2 millions. Another company from the biotech sector was Lykera Biomed, which specializes in developing innovative therapies to treat cancer and aimed to raise €400,000.
Subtilis Biomaterials, a spin-off of the Polytechnic University of Catalonia (UPC) and the winner of the 7thBioEmprenedorXXI award, is also going full-steam ahead, requesting €1.5 millions at the Healthcare Investment Forum to launch its bone-regeneration products. The healthcare sector was also present, represented by Mint Labs –a technology-based company specializing in neurology through 3D mapping of the human brain– seeking an investment of €250,000. PeopleGenetics, which focuses on marketing genetic tests for personalized recommendations, and eHumanlife, an e-Health platform that puts patients in touch with doctors, also presented their projects to attract the attention of investors and raise the capital they need, which was €300,000 and €400,000 respectively.
Health services and equipment and medical devices were also represented among the companies selected. UsMiMa –a start-up that came out of the Moebio d·HEALTH Barcelona program (an initiative of Biocat) and winner of the 2014 BioEmprenedorXXI award– is developing a device to provide a non-pharmacological, non-invasive solution to chronic constipation without side effects. To move forward with the project, they were looking to raise €100,000. And, finally, Transmural Biotech, a spin-off of the University of Barcelona (UB), was seeking €700,000. Their mission is to develop innovative products and services for the clinical setting by applying image-analysis technology to facilitate better, non-invasive diagnosis at a lower cost to the healthcare system. The product they have developed is called quantusFLM, which is a fetal lung-maturity test based on analysis of an ultrasound.
You can learn more about these eight companies watching the presentations at the Youtube channel of the Barcelona Medical Association (COMB).